Metformin Disappoints in Two Phase 2 Lung Cancer Trials Metformin Disappoints in Two Phase 2 Lung Cancer Trials
Although well tolerated, metformin did not improve survival when given alongside chemoradiotherapy to patients with locally advanced non-small cell lung cancer (NSCLC).Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
More News: Cancer | Cancer & Oncology | Fortamet | Health | Hematology | Lung Cancer | Metformin | Non-Small Cell Lung Cancer